English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Tacrolimus is a key immunosuppression drug in solid organ transplantation with a narrow therapeutic index. Twice-daily brand tacrolimus Prograf to once-daily brand tacrolimus Advagraf conversion was proven to be safe as was Prograf to twice-daily generic tacrolimus (Sandoz). Our group previously published the first study comparing the clinical outcomes of renal transplant patients switched from Advagraf to generic tacrolimus with good results at 9-month follow-up. We sought to find if the conversion was still considered safe at 36 months. We included patients with stable renal function, serum creatinine less than 2.0mg/dL, transplanted for 6months or longer. Tacrolimus conversion was performed on a 1 mg:1 mg basis. Thereafter, doses were adjusted to maintain target trough levels between 5 and 10 ng/mL. Our main endpoints were patient and graft survival at 12, 24, and 36months. Secondary endpoints included evolution of serum creatinine

Impact of Conversion From Advagraf to Twice-Daily Generic Tacrolimus in Kidney Transplant Recipients: A Single-Center Study—A 3-Year Follow-Up